Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
; : 781-789, 2015.
Article
de En
| WPRIM
| ID: wpr-74285
Bibliothèque responsable:
WPRO
ABSTRACT
PURPOSE: There is no standard second-line regimen for malignant melanoma patients with disease progression after first-line chemotherapy, and platinum-alkylating agents combined with paclitaxel have shown modest efficacy. MATERIALS AND METHODS: We conducted a phase II, open-label, single-arm study to test the efficacy of docetaxel combined with carboplatin for malignant melanoma patients who failed previous treatment with dacarbazine. Intravenous docetaxel (35 mg/m2 on days 1 and 8 of each cycle) and carboplatin (area under the curve 3 on days 1 and 8 of each cycle) was administered every 21 days. Primary end point was objective response rate (ORR). RESULTS: Thirty patients were enrolled in the study, and the median follow-up duration was 19.8 months. Among 25 per-protocol patients, there were three responders (1 with complete response and 2 with partial response) and 17 stable disease patients (ORR, 12.0%). Among the per-protocol population, the median progression-free survival (PFS) was 4.3 months and the median overall survival (OS) was 9.6 months. Uveal melanoma patients (n=9) showed the best prognosis compared to other subtypes (median PFS, 7.6 months; OS, 9.9 months). The most common grade 3 or 4 adverse event was neutropenia (n=15, 50.0%). CONCLUSION: Docetaxel combined with carboplatin showed association with an acceptable safety profile and overall efficacy for patients with malignant melanoma who had progressed on chemotherapy containing dacarbazine.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Pronostic
/
Études de suivi
/
Carboplatine
/
Paclitaxel
/
Survie sans rechute
/
Évolution de la maladie
/
Dacarbazine
/
Traitement médicamenteux
/
Mélanome
/
Neutropénie
Type d'étude:
Guideline
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limites du sujet:
Humans
langue:
En
Texte intégral:
Cancer Research and Treatment
Année:
2015
Type:
Article